Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?
Objective: Valosin-containing protein (VCP) mutation causes a multiorgan disease characterized by inclusion body myopathy, Paget disease and frontotemporal dementia, more rarely by Charcot-Marie-Tooth disease type…Increased Prevalence of Thyroid Disease in Cervical Dystonia
Objective: This study evaluated the hypothesis that autoimmune disorders may be more common in cervical dystonia (CD) than neurological controls. Background: Although there are many…Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months
Objective: The main objective was to determine if α-synuclein could be modulated by niacin supplementation, contributing to improved Parkinson’s disease (PD) symptoms. Background: Niacin supplementation…A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design
Objective: To describe the study design of a Phase 1b to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in individuals with…4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS
Objective: The aim is to report a case of a 4 yearlong postpartum autoimmune chorea secondary to incomplete SLE/APS. Background: Chorea is a movement disorder…Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra
Objective: To characterize neuroinflammatory gene expression in microglia and astrocytes associated with early alpha-synuclein (a-syn) inclusion formation. Background: Parkinson’s disease (PD) is characterized by alpha-synuclein…Alteration of the fecal microbiota in Turkish patients with idiopathic Parkinson’s disease
Objective: To determine whether the gut microbiota is altered in Turkish patients with Parkinson Disease (PD) and the potential effect of gut microbiota on pre-motor…In-vivo measurement of tau depositions in anti-IgLON5 disease with 18F-PI2620-PET
Objective: The aim of the study was to examine the potential of the second-generation tau-PET tracer 18F-PI2620 to detect tau deposition in anti-IgLON5 disease. Background:…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 25
- Next Page »